Technical and scientific arguments strongly support polypharmacology, drug repurposing and collaborative drug discovery approaches. In opposition are people / cultural issues that tend to a pessimistic viewpoint. Societal value of efforts in academia versus industry in these areas is unclear. Is there an aspect of academic culture that directs to a higher error rate and lack of confidence compared to work performed in industry? Bias and error in academic biology is well documented as are errors in public chemistry databases. Both academic target identification errors and public database chemistry structural errors are common. Peer reviewed publication pressure induces bias and error. �Hypothesis driven research� can select for high error rates. Unknown is how industry compares to academia in terms of bias and error. How do the internal pressures of metrics, stage gates and timelines in industry compare to the pressures of publish or perish in academia?

Polypharmacology, drug repurposing and collaborative drug discovery: Shining light or flash in the pan?

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.